Drug intelligence / Profile preview

RENB-HV-12

Development stage: Preclinical
Lead developer: Renovaro
Modality: Vaccines & Immunotherapeutics

Overview

RENB-HV-12 (formerly ENOB-HV-12) is an investigational therapeutic HIV vaccine candidate being developed by Renovaro BioSciences (formerly Enochian BioSciences). The program was originally licensed from Weird Science and is designed to treat established HIV infection by stimulating the host immune system to control or eliminate the virus. The candidate is currently undergoing preclinical evaluation in non-human primate (NHP) models at the Fred Hutchinson Cancer Research Center, a study overseen by Dr. Hans-Peter Kiem. The research involves collaboration with the University of Pennsylvania, which provided specific viral strains for the NHP studies to evaluate the vaccine's potential efficacy.

Other names: therapeutic HIV vaccine

Beyond the preview

Go deeper on RENB-HV-12.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RENB-HV-12.

Explore the full profile